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Prostate cancera b s t r a c t
The Asian Prostate Cancer (A-CaP) Study is an Asia-wide initiative that has been developed over the
course of 2 years. The study was launched in December 2015 in Tokyo, Japan, and the participating
countries and regions engaged in preparations for the study during the course of 2016, including patient
registration and creation of databases for the purpose of the study. The Second A-CaP Meeting was held
on September 8, 2016 in Seoul, Korea, with the participation of members and collaborators from 12
countries and regions. Under the study, each participating country or region will begin registration of
newly diagnosed prostate cancer patients and conduct prognostic investigations. From the data gath-
ered, common research themes will be identiﬁed, such as comparisons among Asian countries of
background factors in newly diagnosed prostate cancer patients. This is the ﬁrst Asia-wide study of
prostate cancer and has developed from single country research efforts in this ﬁeld, including in Japan
and Korea. At the Second Meeting, participating countries and regions discussed the status of prepa-
rations and discussed various issues that are being faced. These issues include technical challenges in
creating databases, promoting participation in each country or region, clarifying issues relating to data
input, addressing institutional issues such as institutional review board requirements, and the need for
dedicated data managers. The meeting was positioned as an opportunity to share information and
address outstanding issues prior to the initiation of the study. In addition to A-CaP-speciﬁc discussions,
a series of special lectures was also delivered as a means of providing international perspectives on the
latest developments in prostate cancer and the use of databases and registration studies around the
world.
© 2017 Asian Paciﬁc Prostate Society, Published by Elsevier Korea LLC. This is an open access article under
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The Second Meeting of the Asian Prostate Cancer (A-CaP) Study,
from 12:30 to 18:00 on September 8, 2016, at St. Mary's Hospital,
Seoul, Korea was attended by representatives of 12 countries and
regions in Asia participating in the study (Hong Kong, Indonesia,
Japan, Korea, Malaysia, Philippines, Singapore, Taiwan, Thailand,
Turkey, and China) and collaborators from the University of Cali-
fornia San Francisco (UCSF), the Peter MacCallum Cancer Centre
(Australia), the University of Queensland (Australia), and the South
Australia Prostate Cancer Clinical Outcomes Collaborative (SA-
PCCOC). Following on from the A-CaP launch symposium in
December 2015,1 members discussed progress dates and addressed
various issues. These included technical challenges in creating da-
tabases and selecting appropriate database creation software; is-
sues relating to raising awareness at medical institutions to ensure
registration of patients; measures to prevent patients dropping out,
institutional review board (IRB)-related issues; points of clariﬁca-
tion concerning input methods and codes; and the importance of
ensuring appropriate data management. Collaborators from the
USA and Australia provided information on similar databases in
their respective countries [Cancer of the Prostate Strategic Urologic
Research Endeavor (CaPSURE), Victorian Prostate Cancer Registry
(V-PCR), and SA-PCCOC]. The following is a summary of the pro-
ceedings of the symposium.
2. Opening
Choung-Soo Kim (Urology Cancer Center, Asan Medical Center,
University of Ulsan College of Medicine, Seoul, Korea) thanked
Hideyuki Akaza (Graduate School of Interdisciplinary Information
Studies, University of Tokyo, Tokyo, Japan) for his preparations for
the launch of the A-CaP in December 2015 and noted that now 10
Asian countries are participating, together with involvement by
collaborators from the USA and Australia. He noted that the
meeting today would signify the start of the A-CaP study. He
expressed thanks to Hideyuki Akaza for making arrangements and
his efforts to procure budgetary allocation.3. Special Lecture: Open Source Activities of Open Source
Electronic Health Record AlliancedOpen Source Information
Technology, Collaborative Innovation
Seong Ki Mun (Open Source Electronic Health Record Alliance;
OSEHRA, Arlington, VA, USA) noted that the essence of OS is
collaboration and making improvements to develop capabilities
that can change over time. OS is an innovative process that is based
on collaboration. OSEHRA was established in 2011 by the United
States (US) Government. It is an independent nonproﬁt organiza-
tion and its mission is to build and support an OS community
engaged in advanced health information technology for patient
care. OSEHRA has a software repository, and facilitates collabora-
tions for both improvements and product management and OS
code certiﬁcation. There is also a national standard that applies to
OS software, enabling engineers to work on open source software
with conﬁdence.
The original OS softwarewas the Unix operating systemwhich is
popular multi-user, multitasking operating system (OS) developed
at Bell Labs in the early 1970s. This software has become the core of
many commercial products. The preference for OS was a reaction in
Europe to US dominance in software. There are many OS interests
in Europe in many different sectors. There are > 1,000 OS com-
munities around theworld. Many of the cloud computing resources
around the world were developed by NASA (US National Aero-
nautics and Space Administration), and this year, the US Govern-
ment has issued an OS policy.
Engineers think of OS as free software available online. However,
to ensure reliable performance, it is important to have rules of
engagement, a business model, and to engage in efforts to develop
the community and engineers. OS can be thought of as the future of
software, with efforts being led by such organizations as Openstack,
Firefox, GENIVI, and Android.
OS has become prominent in recent US administrations and
Expresident Barak Obama has advocated open government, which
means open data, sources, and science. This is similar to the way in
which A-CaP will be seeking to collaborate and strategize about
ways to deal with prostate cancer.
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and enhance. It is possible to copyright OS software and license it
for others to study, modify, and distribute. There are many OS
licenses, but OS is license free. It can be used as is, but can also be
made into commercial products.
The US Department of Veterans Affairs provides comprehensive
care to > 8.3 million veterans each year through 1,500 hospitals and
uses VistA software for electronic records to run these hospitals.
VistA installations are situated at 2,500 sites globally. The way the
VistAhas been implementeddiffers among facilities and locations in
the US, and other countries are in discussions to use VistA. Jordan
has adopted VistA across the country and no longer relies on
external consultants, and has 140 technicians, 90 engineers, and 50
project management staff members. Jordan is now capable of
providing support to other countries, including others in theMiddle
East. Software constantly needs to be managed and OS life cycles
involve code improvements that result in product improvements.
Precision medicine has become a buzz word in recent years and
big data and analytics involves medical, genomic, lifestyle, and
behavioral data to compile personalized therapy that is best for the
patient. For this to work effectively, it is essential to ensure that
data sharing, standards, and analytics are all OS and open collab-
oration. The best science and services will result in the best care
and it is to be hoped that the A-CaP study will have such outcomes.
3.1. Discussion
Matthew Cooperberg (UCSF) noted that he had been using VistA
for 16 years, but now it lags behind other electronic medical records
framework systems. He asked how to engage with patients and
citizens in order to drive change in the right direction. Seong Ki
Mun responded that OSEHRA is in the process of revamping the
VistA software. It organizes work groups that look at particular
issues and ensures that the outcomes of these work groups are
linked to better overall products. It is important to be responsive to
needs and use the feedback from work groups.
Shiro Hinotsu (Okayama University Hospital, Okayama, Japan)
noted that new drug application companiesmust send Clinical Data
Interchange Standards Consortium (CDISC) standard datasets to
government, which are also OS. He asked about system applications
of OSEHRA for CDISC. Seong KiMun responded that the power of OS
is that users can look at the computer code themselves and
competent end users have control over what they use. The problem
with OS is that there are too many unregulated changes because
sometimes end users want to do their own thing. OSEHRA seeks to
maintain a certain degree of standardization.
4. Report of Korea Prostate Cancer Study and Japan Prostate
Cancer Study and presentation of status of registration for
A-CaP
4.1. Japan Prostate Cancer Study
Shiro Hinotsu noted that the Japan Prostate Cancer Study (J-CaP)
aims to evaluate the trends and outcomes of hormone therapy for
establishing an adequate guideline for hormone therapy for pa-
tients who had newly started hormonal therapy between 2001 and
2003. In 2016, the follow-up period was terminated. J-CaP provides
a secure database and eligible institutions can connect to the server
using an issued identiﬁcation number and password.
The original J-CaP study consisted of background, treatment,
adverse events, survival data, and laboratory data. The majority of
patients were registered in general hospitals, with a smaller pro-
portion registered in university and private hospitals. The most-
used initial hormone therapy is luteinizing hormone releasinghormone þ antiandrogen and combined with surgical castration
(SC) þ antiandrogen. These two account for ~60% of all therapy for
prostate cancer in Japan. The percentage of patients receiving
combined androgen blockade increases depending on the staging.
The Japan Cancer of the Prostate Risk Assessment (J-CAPRA)
score was developed as a tool for discussion, based on data from J-
CaP and the Cancer of the Prostate Strategic Urologic Research
Endeavor (CaPSURE). In terms of survival analysis, progression-free
survival is 4.93 years after primary androgen deprivation therapy,
over 13 years of follow-up. Overall survival has a median of 12.2
years after PADT. In terms of progression-free survival by J-CAPRA
score, a high-risk score is  8 and patients with a lower risk score
have been shown to survive longer.
The J-CaP database is large and provides a wealth of data. For
example, it has been used to study cause of death and the number
of cardiovascular events. An Innovative Study-I was implemented
in which patients were able to select between hormone therapy or
prostatectomy, and the study has engaged in follow-up of these
patients. The J-CaP study data have supported the compilation of
many academic papers.
In summary, the J-CaP study comprises long-term follow-up
data and has a large number of registered patients. It provides a
data source as a novel risk assessment tool. The J-CAPRA score has
been developed, which is useful for international comparisons.
However, the data structure deﬁnition is important because only
collected factors can be used for the tool. The J-CaP database can
also be used for subgroup analysis.
4.1.1. Discussion
Tadaichi Kitamura (Faculty of Medicine, University of Tokyo,
Tokyo, Japan) asked about how many papers have been published
based on the J-CaP study. Shiro Hinotsu responded that ~20 papers
have been published. Jasmine Lim (Faculty of Medicine, University
of Malaya, Kuala Lumpur, Malaysia) asked whether net survival
analysis or relative survival analysis had been performed. Shiro
Hinotsu responded that there are data on prostate cancer deaths,
other cancer deaths, or other deaths. It is possible to ﬁnd cancer-
speciﬁc survival, but what the study focused on was the three
kinds of survival data that had been presented.
4.2. Background factors and health-related quality of life in radical
prostatectomy or ADT for localized prostate cancer
Yasuhide Kitagawa (Graduate School of Medical Science, Kana-
zawa University, Kanazawa, Japan) reported on a retrospective
study in which the outcomes of radical prostatectomy or primary
hormone therapy were compared. The disease-speciﬁc survival for
patients was surprisingly similar after 10 years, but disease-speciﬁc
survival according to histological grade differed.
J-CaP Innovative Study-I was implemented for localized prostate
cancer [T1c T2N0M0, 67e76 years, prostate-speciﬁc antigen (PSA)
< 20 ng/ml]. A total of 1,240 patients were initially registered and
analysis was ﬁnally conducted on 859 patients who underwent
prostatectomy and 381 patients who underwent hormonal therapy.
In general in Japan, the proportion of patients undergoing PADT is
~10%, but in this study the proportion was 30%. The mean age of
both the groups was 71.0 years and 73.0 years, respectively, and
that of the hormonal therapy group was higher than that of the
prostatectomy group. The PSA level was higher in the PADT group.
In both groups, patients with stage T1c cancer were the most
common, constituting ~65% in each group. In addition, patients
with stage T2a cancer accounted for 30.6% in the prostatectomy
group and 21.6% in the hormonal therapy group.
Considering that most patients in the study were elderly, it is
natural that many patients had some coexisting diseases. It was
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therapy because the risk of operation was high owing to the risk of
cardiovascular or respiratory disease.
The reasons for the selection of the treatment regimen and who
made the decision regarding the treatmentwere investigated. In both
groups, the patients’ choice of treatmentwas amajor factor. Itmay be
that younger age is a factor in the decision regarding the operation,
and comorbidity is the reason why the patients choose PADT.
The results of quality of life (QOL) according to Short Form (SF)-8
were shown in the prostatectomy group. SF-8 contains eight scales
that generate physical andmental component summary scores. The
scores of each domain, except for mental health, for the radical
prostatectomy group decreased at 3 months following surgery.
However, their scores returned to pretreatment levels 1 year
following surgery. The mental component summary score
increased over time. By contrast, the scores of some domains for the
PADT group decreased, including physical function. However, the
scores for mental health increased during 1 year of treatment.
In terms of the results of the Expanded Prostate Cancer Index
Composite (EPIC), the completion rate of EPIC was similar to SF-8.
The mean urinary scores for surgical patients decreased at 3
months post-treatment and improved at 12 months, but remained
lower than those at baseline. The section of hormonal function in
the EPIC questionnaire includes hot ﬂashes and breast tenderness,
therefore, the scores of patients receiving PADTgradually decreased
over time, compared with those of surgical patients. The mean
score of the sexual domain was already low at baseline, declined
after 3 months of treatment, and did not return. The difference in
urinary and sexual QOL scores between surgical patients and pa-
tients receiving nerve-sparing and non-nerve sparing procedures
was not clinically signiﬁcant.
In terms of the overall satisfaction scores of each group, the
numbers of patients with increased and decreased satisfaction
were almost equal in the prostatectomy group. By contrast, in the
PADT group, the average satisfaction tended to increase during the
1-year treatment period. Patient selection was higher in the PADT
group and patient hope may therefore reﬂect patient satisfaction.
Many patients may prefer noninvasive treatment and this is why
many patients in Japan select PADT.
4.2.1. Discussion
Levent N. Türkeri (Turkish Urooncology Association, Turkey)
noted that it seems that there is a discrepancy between Western
countries and Japan in terms of treatment. Yasuhide Kitagawa
responded that the result is from clinical studies and < 10% of
localized prostate cancer cases received PADT in Japan, which is
similar to other Asian countries. However, the adverse effect of car-
diovascular disease is lower in Japan than in other countries. Hide-
yuki Akaza added that Shiro Hinotsu had shown a graph showing
cardiovascular events with people who had undergone treatment
and those who had not. There was no signiﬁcant difference and
therefore concerns of cardiovascular risk are not as great as in Japan.
Robert A. Gardiner (University of Queensland Centre for Clinical
Research at Royal Brisbane & Women's Hospital, Brisbane, QLD,
Australia) noted that as Western men age they tend to become
hypogonadal and asked if this is also the case for Japanese men.
Mikio Namiki (Graduate School of Medical Science, Kanazawa
University, Japan) noted that the average testosterone level is lower
in Japanese than Western men.
Matthew Cooperberg noted that, even in theWest, the impact of
ADT on cardiovascular endpoints is controversial. There has been a
large meta-analysis that showed no impact. There may be a selec-
tion bias in that the sickest patients are put on ADT. Cancer survival
was much better in Japan in comparisons between J-CaP and CaP-
SURE. This is interesting and there is still no deﬁnitive answer.4.3. Smart care for prostate cancer using the Internet of Things and
artiﬁcial intelligence (Korea Prostate Cancer Study)
Ji Youl Lee (St. Mary's Hospital, The Catholic University of Korea,
Seoul, South Korea) noted that the trend in medicine is moving
towards precision medicine, big data, smart medicine, and artiﬁcial
intelligence (AI). IBMWatson is famous for AI for Medicine and now
Watson Genomic Analysis. The future direction for prostate cancer
is precision medicine using AI and the Internet of Things because
prostate cancer is heterogeneous. It may be possible to use AI for
prostate cancer in order to detect Gleason scores more accurately,
among other uses. The major issues for precision medicine are
medical informatics (big data), bio-banking, genomic proﬁling
(nanodata), and the integration of big and nanodata.
To create a clinical decision supporting system, it is important to
create a smart clinical database (phenotype), engage in bio-banking
and create genomic databases. The Catholic Prostate Institute has
created an Electronic Genomic Medical Record system, comprising
imaging and prostate bio-banking. The Korea Prostate Bank has
been used to publish many papers.
In terms of smart databases, the Korea Prostate Cancer Study (K-
CaP) database was created in 2012 and is now supported in mul-
tiple languages, andmany papers have been published based on the
K-CaP database.Work is still ongoing to integrate database systems.
St. Mary’s Hospital is famous in Arab countries and many patients
from the United Arab Emirates, Russia, and China come to Seoul for
treatment. Telemedicine is therefore important for these patients
and a smartphone application has been developed to respond to
their needs, including an Arabic language version. Memorandum of
understanding (MOUs) have been concluded with many in-
stitutions on the use of the application.4.3.1. Discussion
Yoshihiko Hirao (Osaka Gyoumeikan Hospital, Osaka, Japan)
noted that AI is important for decision-making, but asked whether
it is readily accepted by patients. Ji Youl Lee responded that, for
prostate cancer, it is difﬁcult to determine the appropriate treat-
ment. If AI could provide a clinical decision-supporting system,
combining genomic and research data, it could give a recommen-
dation about which treatment option is best for the patient. The
Gleason score is important for active surveillance, but perhaps it
would be possible to rely more on AI. AI is a decision-making-
supporting system.
Shigeo Horie (Juntendo University Graduate School of Medicine,
Tokyo, Japan) noted that in statistical analysis it is normal to
eliminate confounding factors and asked how AI could deal with
such confounding factors in decision-making. Ji Youl Lee responded
that for clinical applications it is imperative to consider many op-
tions. There is no remarkable genomic marker in prostate cancer
and so it is necessary to use multiple genomic factors, fromwhich a
decision can be made on which decision would be best.5. Present status of the registration for A-CaP in each country
5.1. Hong Kong
Ng Chi Fai (Division of Urology, The Chinese University of
Hong Kong, Hong Kong) noted that Hong Kong has already
applied for approval and three out of nine hospitals with
coverage of > 40% of the population has been achieved for
registration in the A-CaP study. The REDCap (Research Electronic
Data Capture) system is being used to collect data and this sys-
tem provides a good basis to collect data and has inbuilt mea-
sures to eliminate duplication.
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centers to participate, although this will depend on funding and
manpower.
5.1.1. Discussion
Shiro Hinotsu noted that REDCap is a cloud server and asked
how it is utilized. Ng Chi Fai responded that once the software is
downloaded the information is stored on the hospital server. Teng
Aik Ong (Faculty of Medicine, University of Malaya, Kuala Lumpur,
Malaysia) noted that in Malaysia REDCap is also used and the in-
formation is stored on hospital servers.
5.2. Taiwan
Tong-lin Wu (Kaohsiung Veterans General Hospital, Kaohsiung,
Taiwan) noted that, after the previous A-CaP meeting, the Ethics
Committee of his hospital had agreed to waive consent. To date, 83
patients have data completed, but half of them are from 2015. He
raised the issue of ﬁnding a coding method. There are also other
questions that need to be considered, which include the following.
How to deﬁne lethal prostate cancer?With regard to the number of
positive biopsy cores, how about diagnosis with transurethral
resection of the prostate? With regard to T stage, should this be
done using the American Joint Committee on Cancer staging alone,
or also with magnetic resonance imaging?
5.3. Indonesia
Lukman Hakim (Department of Urology, Airlangga University/
Soetomo General Hospital, Surabaya, Indonesia) noted that, until
recently, there was no national cancer registry in Indonesia. On
April 24, 2016 a meeting in Jakarta involving eight teaching hos-
pitals was implemented. Representatives were appointed as pri-
mary investigators and local scientiﬁc beneﬁts were explained. A
board of advisors (3 urologists from the 3 largest urology centers)
was appointed and a simple web-based application system was
announced. The enrollment period started on April 1, 2016.The
study has started with six hospitals on Java Island, including the
three largest cancer centers in Indonesia. Fifty-one patients have
been registered from these six teaching hospitals.
In terms of the study algorithm, data collection is implemented
by a study coordinator, who also enters data into the system,
following data veriﬁcation by principal investigators and country
coordinators. The application is currently under reconstruction as it
has limitations. It would be good if Indonesia could use either J-CaP
or K-CaP software. The aim is to enable coordinators to update or
input new data from wherever they are. In terms of patient back-
ground, 64.7% of patients have no history of prostate cancer or le-
thal prostate cancer, although, similar to Taiwan, it will be
important to consider how to deﬁne lethal prostate cancer.
The mean PSA at diagnosis is 361.91 ng/ml and the mean T
category is T2c. In general, among the 51 cases, ADT (without
chemotherapy) was used as the main treatment. Of the 14% who
underwent prostatectomy, all undertook it as ﬁrst-line curative
treatment. ADT was performed mainly as primary treatment and
luteinizing hormone releasing hormone þ antiandrogen þ long-
term antiandrogen was the preferred method used by doctors in
Indonesia. The antiandrogen of preferencewas bicalutamide, which
was used in 91.4% of cases.
In terms of constraints, there is a risk of loss to follow-up and
solutions are being sought by obtaining mobile phone numbers of
the patients and their families. In addition, the limited features of
the current application software are under reconstruction and it
would be appreciated if J-CaP or K-CaP software could be used. InIndonesia the hardcopy of medical documents is still a legal
document and hospitals are required to store them for 5 years.
In terms of next steps, the plan is to involve more satellite
hospitals, implement regular annual meetings, and look into the
potential for using J-CaP or K-CaP software.
5.3.1. Discussion
Kim Moretti (SA-PCCOC, Australia) asked what the median PSA
was. Lukman Hakim responded it was somewhere in the region of
150, which is still high. Jason Letran (Cardinal Santos Medical
Center, Manila, Philippines) asked who engages in follow-up and
whether it is the physicians themselves. Lukman Hakim responded
that it is the coordinator who contacts patients or their families by
telephone.
5.4. Singapore
Edmund Chiong (National University Health System, Singapore)
reported that there are seven hospitals in Singapore looking after
prostate cancer patients; of which three have individual prostate
cancer databases. There are also a number of observational studies
underway. Three of the academic hospitals have agreed to partic-
ipate in A-CaP. Each has its own existing prostate cancer database.
Prospective data are already available for 100e300 patients. The
proposed platform is REDCap and attempts are being made to
harmonize data ﬁelds and centralize subject identiﬁcation, and
methods developed to eliminate duplication. There are still IRB
issues, but a single multi-institution IRB application for all hospi-
tals for prospective patients is in progress, and informed consent
will be required. Each hospital will retain its own database au-
tonomy and data sharing will require some kind of contractual
agreement.
In Phase 2, once the above has been arranged, the aim is to
combine anonymized data from major hospitals, which have
already been collected in other studies. Modiﬁcations and changes
will be made and there will be some degree of data governance and
oversight. Data sharing with A-CaP will also require some kind of
contractual agreement. The target for Phase 1 to Phase 2 imple-
mentation is 2017 and the aim is to recruit 500e1,000 patients over
the course of 3 years.
In Phase 3 the aim is to combine anonymized data from all
participating hospitals, implement modiﬁcations and changes, and
create a long-term standing database for Singapore. Coordination
with societies, such as the Singapore Urological Association, will be
required. The target for implementation is from 2018.
The Human Biomedical Research Act, passed by the Singapore
Parliament, is a complex piece of legislation that will have a sig-
niﬁcant impact on the way human biomedical research is con-
ducted. The law includes new, criminally enforceable requirements
for consent, documentation, IRB organization and administration,
as well as responsibilities of researchers and research institutions.
Speciﬁc issues are the requirement for individual informed consent
from patients, even in databases. There are difﬁculties with
obtaining “waiver of consent due to impracticability” and there are
issues with recommendations on the “key-holder” for re-
identiﬁcation of patients. This will have implications for data-
sharing agreements and efforts are being made to seek clariﬁca-
tion from the government.
5.4.1. Discussion
In terms of the large foreign community in Singapore, a question
was asked about follow-up of patients in any given study. In
response it was noted that people who are deemed to be unlikely to
be available for follow-up are not registered for the study.
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Jason Letran noted that following the First A-CaPMeeting 2016 a
brain-storming meeting was held in the Philippines and there were
11 training institutions and 20e30 private institutions invited to
attend. In the Philippines most patients with localized prostate
cancer patients are from the private sector. The Philippines does not
have a database of its own and immediately upon receiving an e-
mail from Japan, preliminary activities were implemented and used
to identify potential problems. One of the problems was the tech-
nical limitations of institutions in terms of interest and Wi-Fi ac-
cess. A decision was made to create a booklet and provide training
on how to ﬁll it out. A decision was also made to input data using
Excel (Microsoft Corporation, Redmond, WA, USA) and a research
assistant is dedicated to this study.
As of August 30, 2016 1,000 booklets have been printed and 600
distributed. The total number of booklets received was 57; all of
which have been encoded. The rate of return is only 9.5% at present.
Another problem is the low motivation among practitioners and
residents to ﬁll out the registry. For the study to be sustainable it
will require continuous funding, the training of new practitioners
and residents, additional research assistants as follow-up expands,
and issues with the IRBs and ethics committees require attention.
Strategies to respond to these challenges are close coordination
with the head of the institutions/hospitals on survey conduct, and
provision of incentives for every 10 booklets handed over to the
Philippine Society of Urologic-Oncologists. It will also be important
to make people realize that the data collected will be useful for
their own studies or future research.
5.5.1. Discussion
Lukman Hakim asked how updating of the data is monitored.
Jason Letran responded that once the hard copy of the booklet is
collected and encoded it is returned to the practitioner and is
collected again every few months for updates.
5.6. Malaysia
Teng Aik Ong reported that prostate cancer is the fourth most
common cancer in Malaysian men. Most of the patients were Chi-
nese, followed by Malays. The urological service in Malaysia is
divided into government and private services and 70% of the pop-
ulation will use government services, provided by the Ministry of
Health or Ministry of Higher Education. A-CaP Registry will be built
based on prostate cancer patients attending for treatment in all
government hospitals in Malaysia. There are 12 centers in Malaysia
that offer urology services. The challenge is to get everyone
involved in A-CaP, including urologists at the Ministry of Health. A
letter was received on March 22, 2016 indicating that the Ministry
had approved the initiation of the A-CaP study. Each institution has
provided an annual estimate of the number of prostate cancer
patients. REDCap is the system that is being used. Visits to hospitals
to promote the concept of A-CaP to staff and provide information
are also being implemented.
In terms of the current status, six institutions have already
started and major centers in the Klang Valley are due to begin the
study in the near future. The strategy for 2016 is to receive speciﬁc
approval and seek international and local funding to ensure the
sustainability of the study.
5.7. Thailand
Bannakij Lojanapiwat (Faculty of Medicine, Chiang Mai Univer-
sity, Thailand) reported that from January to July 2016 there were
212 new cases of prostate cancer, including 39 in Chiang MaiUniversity Hospital. These are government health-system-covered
cases and private cases are not included. Although these patients
have been registered, they have not yet been input into a system for
A-CaP, but once information has been received fromMalaysia about
REDCap, the input of data will begin.
In terms of staging, most cases are T3 and T4 and there is more
localized prostate cancer to be found in Bangkok. The challenges
that need to be overcome are to manage the workload that is faced
with other diseases. There are only 350 urologists in Thailand for a
population of 67 million. It is hoped that the A-CaP study will gain
greater support and awareness and a budget can be procured to
ensure the sustainable implementation of the study.
5.7.1. Discussion
Hideyuki Akaza noted that there seems to be differences among
institutions on the type of castration provided. Bannakij Lojanapi-
wat responded that there is a decreasing amount of surgical
castration, but it is still used in some institutions due to costs and
availability of medical castration. It is recently the case that medical
castration was covered under the national health system.
5.8. Korea
Kim Wun-Jae (Chungbuk National Medical University Hospital,
South Korea) reported that registration for the A-CaP study had
already started in Korea. Prostate cancer incidence was 8.2% in
Korea in 2012, which is lower than in Western countries, but the
percentage continues to increase. In terms of the changing patterns
of primary treatment in Korea, there has been an increase in sur-
gery from 22.4% to 45.4%, a reduction in ADT from 60.3% to 45.4%,
and a signiﬁcant increase in radiation therapy from 7.2% to 18.4%. In
multinomial logistic regression analysis, older patients showed a
signiﬁcant association with ADT or radiation therapy compared to
surgery. Patients with higher incomes showed signiﬁcant associa-
tion with surgery.
Treatment patterns in Korean prostate cancer patients have
changed remarkably over the past 10 years. Sociodemographic
factors do affect the primary treatment choice and it is likely that
they will be important tools for reviewing changing patterns of
primary treatment in Korean prostate cancer patients and planning
future health policy.
From 2007 to 2013 the incidence of prostate cancer doubled in
Korea but mortality decreased. At present, a total of 2,861 cases
have been collected from January 2016 for the A-CaP study.
Approximately 35% of all K-CaP cases are expected to be included.
Of the already registered patients, the most used therapies are
radical prostatectomy (62%) and hormonal therapy (28%). The
proportion of radical prostatectomy cases registered for A-CaP is
larger than the nationwide average and the proportion of hormonal
therapy cases under A-CaP is smaller than the nationwide average.
In terms of future steps, it will be necessary to consider whowill
participate in the A-CaP Scientiﬁc Committee, which is the most
important part of A-CaP. It should also be recognized that data input
for the purposes of A-CaP can be time consuming and ways should
be considered to decrease time burden of input.
5.8.1. Discussion
Mikio Namiki noted signiﬁcant differences among the patients
included in the A-CaP study and the nationwide average and asked
whether it would be possible to include hospitals other than the
major institutions in Seoul. Kim Wun-Jae responded that other
hospitals are included in K-CaP and it could be expected that these
hospitals would be included in A-CaP if a format similar to K-CaP
were used. Hideyuki Akaza noted that for the A-CaP study ~140
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~20,000 cases will be registered in Japan.
5.9. Turkey
Levent N. Türkeri reported that an epidemiological study was
implemented to investigate the incidence of prostate cancer in
Turkey. It was designed and executed by the Uro-Oncology Asso-
ciation of Turkey, supported by the Ministry of Health. All cases of
prostate cancer in selected areas of the country have been regis-
tered, with 6,693 cases registered, and 12 cities participating. The
age-adjusted incidence rate is ~36 per 100,000, which is similar to
that in Northern Mediterranean countries. Most patients are > 55
years of age and are concentrated around 65e69 years.
The Uro-Oncology Association has engaged in efforts to create a
registry, and a committee was established for that purpose,
comprising ﬁve expert urologists, one statistician, and two software
experts. This committeemade an ofﬁcial start on registering patient
records in September 2015. A web-based system has been devel-
oped for registering patient data and it is similar to the format for
A-CaP registration. The registration form includes a general infor-
mation page, medical history page, diagnosis page, biopsy page,
staging page, treatment page, radical prostatectomy page, QOL
page, and follow-up and status at last follow-up pages.
The prostate cancer database has a total of 188main data points;
most of which are accessed from drop-down lists. Six hundred and
ﬁfty patients have been recorded and one of the major problems is
the absence of dedicated data managers. Efforts are being made to
recruit data managers through the Uro-Oncology Association,
which imposes a ﬁnancial burden on the Association. Turkey can
participate in A-CaP given that there is a functional registration
system in Turkey and it is anticipated that it will be a fruitful
collaboration.
5.9.1. Discussion
Yoshihiko Hirao asked if PSA screening is implemented in
Turkey. Levent N. Türkeri responded that there is a high degree of
awareness of PSA in Turkey, which has been driven by media ef-
forts. This is perhaps the reason why many cases are identiﬁed
earlier.
Frank Gardiner asked about the maintenance of QOL data; to
which the response was that the data mangers that have been
employed are doing their best to keep data up to date. Dedicated
data managers are being trained by a private company with the
speciﬁc aim of maintaining the database.
6. Special Lectures II
6.1. Report from CaPSURE
Matthew Cooperberg noted that approximately one-third of all
CaPSURE patients (~5,000 in total) are still being followed. There
are now > 190 publications arising from CaPSURE, and various risk
instruments have been developed and validated. There has been a
sea change in therapy in the USA, including more watchful waiting
and less ADT. In terms of QOL it has been found that differences
among treatments tend to attenuate over time.
CaPSURE was the original source of data for CAPRA and the ﬁrst
source of validation statistics for the J-CAPRA score, and has
resulted in a number of validation studies. The CAPRA score is
moving towards national standards of care and it is hoped that it
will provide an alternative as a risk stratiﬁcation tool.
In terms of the future for CaPSURE, tracking real-world use of
medication for castration-resistant prostate cancer is a major
challenge. Data input is time consuming and there is little appetiteto do this among practitioners. It is anticipated that once current
funding runs out that the registration of cases for CaPSURE will end
and migrate to the American Urological Association Quality Regis-
try (AQUA), but the monitoring of existing CaPSURE patients will
continue, including cases of advanced prostate cancer. Thousands
of data points have been collected on imaging, treatment, and
outcomes.
Another effort is a retrospective effort to acquire biomarkers.
Through a 2012 Transformative Impact Award from the Depart-
ment of Defense collections of formalin-ﬁxed parafﬁn-embedded
biopsy and prostatectomy tissue specimens has started, along with
saliva for germline DNA from CaPSURE participants. The Depart-
ment of Defense project focuses on low-risk disease and it is hoped
that this will be followed up with higher-risk disease in the near
future. This will be one of the only biomarker projects including
men treated with different modalities, and with long-term follow-
up including QOL.
Efforts are also being made to analyze the genomic landscape of
prostate cancer and this is an area that will be of increasing
importance in the future, with a view to molecular subtyping of
prostate cancer, as has been the case for breast cancer for many
years.
AQUA collects detailed national processes and outcomes data for
patients with urological diseases. The primary goal is quality
assessment and improvement through local feedback to practices.
Secondary goals are to fuel next-generation health services
research and clinical/outcomes research, and inform urology policy
efforts. There are 380 urology sites and 2,154 providers that have
joined AQUA. Data are available from ~50 sites and the country is
well covered, and discussions are underway with the University of
Toronto, Toronto, Ontario, Canada with a view to expanding the
database beyond the USA. It is possible to pull structured code from
the AQUA database. There are also methods to ﬁnd Gleason scores
that are embedded in the text, as well as initiatives to collect
patient-reported outcomes (PROs) at the national level.
In parallel with AQUA, UCSF has been leading dictionary
development efforts and is on the EPIC, an electronic medical re-
cords system. EPIC was not written originally for data collection,
but it has the capabilities to create data from notes. The UCSF data
model is gradually working its way into the national system
through AQUA.
AQUA has successfully registered 15,682 newly diagnosed pa-
tients over 2 years, which is faster than the time taken for CaPSURE.
Although the data dictionary is not as comprehensive as CaPSURE,
it is likely that 100,000 cases will be recorded. The latest (pre-
liminary) data suggest that trends are changing and there is a move
towards active surveillance and watchful waiting.
In summary, it is hopeful that prostate cancer studies based on
Medicare will disappear, with data based on coding/billing data
being replaced by prospective registries working from the point of
care and integrating PROs. CaPSURE will continue as a gold stan-
dard disease registry with unparalleled depth and follow-up as the
AQUA score and size will expand rapidly. Internationally consti-
tuted studies like A-CaP will provide unique insights into prostate
cancer epidemiology. It is hoped that in the future it will also be
able to routinely integrate genomics with registries.
6.1.1. Discussion
Levent N. Türkeri askedwhether there is any difference between
radical prostatectomy samples and biopsy samples in terms of
representativeness. Mathew Cooperberg responded that the aim is
to seek whatever materials are available. The representativeness of
the biopsy depends on how well the biopsy is done. It is not
possible to know until specimens are actually collected. The other
source of biomarkers is the use of saliva samples and these are
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Frank Gardiner noted that one of the problems is that more is
not necessarily better. There is heterogeneity and it may be better
to focus on those cases that could be guaranteed as being quality
information. Matthew Cooperberg responded that for questions of
tracking practice patterns and doing real-world comparative
effectiveness studies, it will be important to reach the national
level. CapSURE focuses on major centers rather than smaller in-
stitutions and AQUA is also a similar exercise, therefore, these
provide an optimistic picture compared to what is happening
across the country. This is why it is important to expand registra-
tion to the national level.6.2. Prostate cancer registries: Perspective from Australia
Declan Murphy (Peter MacCallum Cancer Centre, Melbourne,
VIC, Australia) reported that although mortality rates from 1982 to
2014 have gone down, there is still a high incidence of prostate
cancer in Australia. The paper titled “Prostate cancer registries:
current status and future directions” concluded that the strengths
and limitations of prostate cancer registries should be carefully
considered when planning studies using these databases. Although
randomized controlled trials still provide the highest level of evi-
dence, large registries play an important and growing role in
advancing prostate cancer research and care.
The Victorian Prostate Cancer Registry (V-PCR) was established
in 2008 and has accumulated ~19,000 patients (~90% of all patients
in Victoria). The goals were to provide information patterns of care
following diagnosis of prostate cancer; to monitor quality of care
for men diagnosed with prostate cancer; and to provide a platform
for further research of prostate cancer. The hospital sends notiﬁ-
cation to the Victorian Cancer Registry, after which the hospital
sends an explanatory statement and letter of invitation to partici-
pate. The Victorian Cancer Registry then sends the patients’ biopsy
results to the V-PCR. V-PCR staff collect patients’ results from the
hospital and phone patients at 12 months and 24months to engage
in a follow-up questionnaire.
There has been successful recruitment to the V-PCR and there
are now 35 sites engaged in recruitment, with 100% clinician opt-in
and 98% patient opt-in. In terms of PROs, urinary dysfunction is not
reported as much as sexual dysfunction.
One reason that there is good participation in the registry is
that the registry sends out reports to clinicians and hospitals on
their performance. These reports include such items as mortality
rate, positive margins, documentation of cT stage in medical re-
cords, biochemical recurrence at 24 months, and QOL. Clinicians
can see their own standing on a graph that shows positive sur-
gical margins and can take steps to reduce these margins. The V-
PCR also helps to measure changes in quality by monitoring
changes in three process quality indicators. Monitoring the
quality of care is also a key aspect, and since 2010, a 21% reduction
in the rate of low-risk patients undergoing active treatment has
been achieved.
In summary, V-PCR serves as an excellent disease-speciﬁc reg-
istry with almost population-level data capture. Quality indicators
available to clinicians and hospitals and good publications are now
emerging. Improvements in quality in a number of domains have
been achieved and moves are being made to expand the initiative
nationally and also binationally to include New Zealand.
A future development is the Prostate Cancer Outcomes Registry
(PCOR), which is funded byMovember. It may be useful for A-CaP to
alignwith the Movember Foundation and perhaps seek funding for
similar registries.6.2.1. Discussion
Frank Gardiner asked about stumbling blocks to alignment be-
tween V-PCR and A-CaP. Declan Murphy responded that the major
stumbling block is standardizing datasets. This would be a good
thing to aspire towards but will take time. In Australia and New
Zealand the indigenous populations have poor outcomes and it will
be interesting to see what disparity there is among ethnic pop-
ulations across Asia as a whole.
6.3. Report from SA-PCCOC data (Australia)
Kim Moretti reported that SA-PCCOC was established in 1998
and its mission is to improve understanding of prostate cancer in SA
by monitoring the clinical proﬁle of patients and their treatment
and clinical outcomes, and thus improve care of prostate cancer
patients through the provision of appropriate reports and analyses
to clinicians and health planning bodies that are responsible for
their care at the State level.
The SA-PCCOC Registry is a prospective disease-speciﬁc registry
and longitudinal observational study comprising consenting men
diagnosed with pathologically proven prostate cancer in SA. Pa-
tients are followed to death or withdrawal. Patients want to know
certain things and therefore PROs have been collected from
inception of the Registry, including a baseline. The Registry is also
compliant with the Australian Commission on Safety and Quality in
Health Care Clinical Quality Registries Framework.
The registry has 11,400 patients for a population of 1.45 million
and there are good collection systems. It is long running, with 18
years of follow-up and there is a lot of data completeness and data
quality. Three party-collected patient reported outcome (PROs) are
12-item short form health survey (SF12), expanded prostate cancer
index composite 32 (EPIC32) and international prostate symptom
score (IPSS).
The Registry started in 1998 with one surgeon, and as of 2016, it
has achieved population coverage of 95%. Governance is critical and
it is a requirement to have consumer representatives on SA-PCCOC
and other bodies, because the two major funding bodes will not
provide funding unless there is a public representative on it.
SA-PCCOC is multidisciplinary, which is important and is also
something that is mentioned in the protocol of A-CaP. Ensuring and
maintaining growth are important and there has been a move from
an opt-in to an opt-out system.
In terms of the changing proﬁle of prostate cancer in SA, radical
prostatectomy and radiotherapy have decreased in recent years,
with an increase in surveillance and watchful waiting. PROs are
important and they have been collected since the start of SA-
PCCOC. PROs include urinary and sexual functions. Data show
substantial changes in prostate cancer presentation and manage-
ment over the past 16 years and improvements in prostate cancer
survival.
Collaborative research is important for maintaining a database.
Publications and presentations have been increasing in recent
years, including 13 presentations at international conferences.
There are currently 29 projects underway and eight publications
have been issued in 2016, a number of them about registries.
It is important to be visible and engage in marketing in order to
ensure the continuation of registries and study groups. Engage-
ment is also important and this can be achieved from various
symposia and conferences. It is also important to be innovative, and
at SA-PCCOC there has been substantial progress made in the
development of new methods and tools for e-collection of data.
In Australia it is mandatory for any diagnosis to be notiﬁed to
pathology laboratories. Therefore, an automated link has been
created whereby SA-PCCOC receives notiﬁcation directly from pa-
thology laboratories. However, SA-PCCOC can only import from the
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coverage is ~95% and Electronic LAB (eLAB) has 111,600 PSA values
that are provided automatically.
A binational prostate cancer outcome registry combining
Australia and New Zealand (PCOR-ANZ) was only recently
completed. Initial discussions were on the registry model, including
how to approach governance and deﬁning the purpose of the
database at the national level. The easiest model to create is a
disseminated extraction model, which is what A-CaP will be. A
centralized clearing house model is one that is the same as CaP-
SURE. The PCOR-ANZmodel is a federatedmodel. In this system the
states own the data and there is an agreement with the central data
custodian. In the case of PCOR-ANZ, Movember required the data-
base to include relevant goals identiﬁed by patients.
Another important factor to bear in mind in terms of core data
sets is to concentrate onminimumnotminimal datasets. The PCOR-
ANZ registry identiﬁed 347 data points and through a Delphi pro-
cess the 80 most common data elements were identiﬁed as Tier 1
for minimum data collection, Tier 2 for anticipated data collection,
and Tier 3 is the value-added platinum standard for data collection.
6.3.1. Discussion
Shigeo Horie asked if SA-PCCOC is funded by the state or other
sources. Kim Moretti responded that funding is from grants and
from the Movember organization. It was also noted that consumer
representatives are important in Australia. In terms of feedback, the
consumer representative works on marketing and awareness-
raising activities.
Frank Gardiner asked about the three tiers for data collection,
noting that the classiﬁcation for TNM is a Tier 1 item in PCOR-ANZ
and SA-PCCOC but it is listed as mandatory for A-CaP. He asked
whether this could be a barrier to integrating Australian and New
Zealand registries with A-CaP. Kim Moretti responded that the
Australian and New Zealand databases are heavily aligned with
International Consortium for Health Outcomes Measurement
datasets, but it is likely that there would not be major hurdles to be
overcome in aligning data registries.
6.4. Special report from USA/United HealthCare (UHC) on prostate
cancer treatment in the USA
Peter Carroll (UCSF) reiterated Shiro Hinotsu’s comments about
the richness of collaboration, as evidenced by CaPSURE and J-CaP. In
terms of prostate cancer in the USA, there has been a big uptake in
the use of radical prostatectomy, and the risk proﬁle of men un-
dergoing this operation is increasingly thosewith high-risk disease.
In terms of predictions for prostate cancer now and in the future
in the USA, the negative public pressure on PSA early detection may
be tempered, but it will not go away. There is increased use of novel
technology to decrease biopsy rates, and an increasing sense that
prostate cancer is a spectrum of disease inﬂuenced by host and
tumor environment. In addition, active surveillance, although
increasingly recognized as a relatively safe option, will be chal-
lenged by focal forms of therapy, and the treatment of high-risk
disease will be better personalized due to the use of advanced
imaging andmolecularmedicine. The big disrupters here are the US
Preventive Services Task Force, tumor biology, changing treatment
paradigms, and payment reform. There has been a decrease in PSA
testing in the USA over time.
In terms of what will save early detection, the key point is that it
has the best impact on quality-adjusted life years saved. In the USAin the next decade, there will be selective detection and treatment,
rather than full detection and selective treatment. Increasingly in
the USA, there are moves toward measures of increased speciﬁcity,
such as use of percent-free PSA, 4Kscore, or Prostate Health Index. A
strategy of sampling only magnetic resonance (MR) regions of in-
terest would result in missed or downgraded Gleason  3þ4 tu-
mors in 29 patients (14%). The real issue is what to lead with,
whether it be Prostate Health Index/4Kscore or multiparametric
magnetic resonance imaging/fusion biopsy, etc.
For ﬁrst-line treatment there is also a changing paradigm. Focal
therapy can beneﬁt only a small proportion of men, and this is a
source of concern. Molecular testing and imaging are likely to save
the day here. Pre-therapy circulating tumor cell (CTC) nuclear
expression of AR splice variant 7 (AR-V7) protein in men with
metastatic castration-resistant prostate cancer is a treatment-
speciﬁc biomarker predicting superior overall survival for taxane
therapy over androgen receptor signaling (ARS) inhibitors in a
clinical practice setting, warranting prospective validation.
Ga-prostate-speciﬁc membrane antigen positron emission to-
mography is now capable of detecting late biochemical failure.
Around 42% of the cases with nodal metastases had positive nodes
located outside the primary landing zone (perirectal, presacral, and
anterior prostate) using this technique.
There is likely to be a conﬂuence of imaging, reﬁned treatment,
andmolecular medicine in the future. Prostate cancer is a spectrum
of disease and it should be assessed and treated as such. It is
important to match the treatment to the patient and his cancer. All
treatment options required greater scrutiny in terms of outcomes,
costs, and appropriateness. It is important to begin collecting and
disclosing patient-reported, risk-adjusted outcomes prospectively,
across multiple treatment modalities, facilities, and geographies.
Furthermore, efforts should be made to develop, validate, and use
novel therapy appropriately.7. Closing remarks
Yoshihiko Hirao expressed appreciation to Hideyuki Akaza for
his initiative in setting up A-CaP. When the idea for A-CaP was ﬁrst
proposed, J-CaP and CaPSURE had already been implemented and
K-CaP was also underway. However, the issue of an Asia-wide CaP
has presented various challenges due to issues of funding and other
logistic matters. It is thanks to the efforts of Dr. Akaza and his
colleagues that A-CaP has made a successful start. Appreciationwas
expressed to Korea for hosting the Second A-CaP Meeting, and in
conclusion, it was stressed that the work of A-CaP is only just
starting and there will be more to do in the future.
Hideyuki Akaza noted that if A-CaP members wish to meet in
Chiang Mai at the 7th Congress of the Asian Paciﬁc Prostate Society
(APPS) in 2017, it will be important to launch a common investi-
gation study that will provide a basis for discussion among all
participants. He thanked A-CaP members and closed the meeting.Conﬂicts of interest
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